Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) FCF Margin (2023 - 2025)

Entrada Therapeutics has reported FCF Margin over the past 3 years, most recently at 2463.13% for Q4 2025.

  • Quarterly results put FCF Margin at 2463.13% for Q4 2025, down 237033.0% from a year ago — trailing twelve months through Dec 2025 was 509.63% (down 48842.0% YoY), and the annual figure for FY2025 was 509.63%, down 48842.0%.
  • FCF Margin for Q4 2025 was 2463.13% at Entrada Therapeutics, down from 1831.54% in the prior quarter.
  • Over the last five years, FCF Margin for TRDA hit a ceiling of 805.0% in Q1 2023 and a floor of 2463.13% in Q4 2025.
  • Median FCF Margin over the past 3 years was 107.73% (2024), compared with a mean of 472.56%.
  • Biggest five-year swings in FCF Margin: soared 25298bps in 2024 and later crashed -237033bps in 2025.
  • Entrada Therapeutics' FCF Margin stood at 9.37% in 2023, then crashed by -890bps to 92.79% in 2024, then crashed by -2554bps to 2463.13% in 2025.
  • The last three reported values for FCF Margin were 2463.13% (Q4 2025), 1831.54% (Q3 2025), and 1506.72% (Q2 2025) per Business Quant data.